Moeez Rathore
Overview
Explore the profile of Moeez Rathore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang T, Yan Y, Yu Z, Rathore M, Lee N, Tseng H, et al.
J Clin Invest
. 2024 Oct;
134(23).
PMID: 39436709
The elevated level of replication stress is an intrinsic characteristic of cancer cells. Targeting the mechanisms that maintain genome stability to further increase replication stress and thus induce severe genome...
2.
Rathore M, Curry K, Huang W, Wright M, Martin D, Baek J, et al.
Gastroenterology
. 2024 Oct;
168(2):300-315.e3.
PMID: 39393543
Background & Aims: Therapy failure in patients with metastatic colorectal cancer (mCRC, ∼80% occur in the liver) remains an overarching challenge. Preclinical studies demonstrated that human epidermal growth factor receptor...
3.
Hajihassani O, Zarei M, Roichman A, Loftus A, Boutros C, Hue J, et al.
bioRxiv
. 2024 Aug;
PMID: 39211182
Pancreatic cancer is the third leading cause of cancer death in the United States, and while conventional chemotherapy remains the standard treatment, responses are poor. Safe and alternative therapeutic strategies...
4.
Vaziri-Gohar A, Hue J, Abbas A, Graor H, Hajihassani O, Zarei M, et al.
Nat Commun
. 2023 Jun;
14(1):3823.
PMID: 37380658
Pancreatic Ductal Adenocarcinoma (PDAC) is highly resistant to chemotherapy. Effective alternative therapies have yet to emerge, as chemotherapy remains the best available systemic treatment. However, the discovery of safe and...
5.
Rathore M, Zhang W, Wright M, Zarei M, Vaziri-Gohar A, Hajihassani O, et al.
J Cancer Sci Clin Ther
. 2023 Jan;
6(4):431-445.
PMID: 36644317
~90% metastatic pancreatic ductal adenocarcinoma (mPDAC) occurs in the liver, and the 5-year survival rate for patients with mPDAC is only at 3%. The liver has a unique endothelial cell...
6.
Zarei M, Hajihassani O, Hue J, Graor H, Loftus A, Rathore M, et al.
J Exp Clin Cancer Res
. 2022 Sep;
41(1):283.
PMID: 36153582
Background: Alternative treatment strategies in melanoma beyond immunotherapy and mutation-targeted therapy are urgently needed. Wild-type isocitrate dehydrogenase 1 (wtIDH1) has recently been implicated as a metabolic dependency in cancer. The...
7.
Rathore M, Zhang W, Wright M, Bhattacharya R, Fan F, Vaziri-Gohar A, et al.
Mol Cancer Res
. 2022 Mar;
20(6):996-1008.
PMID: 35276002
Implications: This body of work highlighted a potential strategy of using HER3 antibodies in combination with standard chemotherapy agents for treating patients with either KRAS wild-type or KRAS mutant metastatic...